Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lymphokine-activated killer cell therapy

Known as: LAK cell therapy, cell therapy, lymphokine-activated killer, therapy, lymphokine-activated killer cell 
The use of lymphokine-activated killer cells in the treatment of any disease or disorder.
National Institutes of Health

Related topics

Related topics

2 relations
Lymphokine-Activated Killer Cellsinterleukin-2/lymphokine-activated killer cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules.
Natural killer (NK) cells have been considered to be a group of lymphocytes lacking clonally distributed receptors for antigens… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2004
2004
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis
SummaryInterleukin-1 (Il-1)-like activity in biological fluids was measured by their ability to rectify the Il-1-dependent… Expand
  • figure 1
  • table 1
Review
2003
Review
2003
IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
IL-21 is a recently described type I cytokine produced by activated CD4(+) T cells that profoundly affects the growth, survival… Expand
Highly Cited
1997
Highly Cited
1997
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
Lymphoreticular malignancies, collectively called posttransplant lymphoproliferative disorders (PTLD), eventually develop in 2-5… Expand
1997
1997
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.
Abstract Cell lymphomas which often contain the Epstein-Barr virus (EBV) make up the preponderance of tumors that collectively… Expand
1996
1996
The conserved lymphokine element-0 in the IL5 promoter binds to a high mobility group-1 protein.
The conserved lymphokine elements-0 (CLE0) in the IL5 promoter is essential for the expression of IL-5. Here, we report the… Expand
Highly Cited
1995
Highly Cited
1995
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of… Expand
  • table I
  • table II
  • figure 1
1994
1994
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
The effects of NG-methyl-L-arginine (L-NMA), an inhibitor of nitric oxide formation, were studied in dogs treated with… Expand
Highly Cited
1990
Highly Cited
1990
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Several groups have described the efficacy of interleukin 2 (IL-2) plus lymphokine-activated killer (LAK) cells in the treatment… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
1989
Highly Cited
1989
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16…
The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE